Clinical trials do support their use as monotherapy agents. Fibrates reduce the number pharmacology of cardiovascular system pdf non-fatal heart attacks, but do not improve all-cause mortality and are therefore indicated only in those not tolerant to statins.
Due to a rare paradoxical decrease in HDL-C seen in some patients on fenofibrate, as per US FDA label change, it is recommended that the HDL-C levels be checked within the first few months after initiation of fibrate therapy. If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline. Atherosclerosis in type 2 diabetes: a role for fibrate therapy? Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review”. Jun M, Foote C, Lv J, et al.
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis”. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome”. Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, et al. This page was last edited on 16 December 2017, at 01:07. 2013 American Heart Association, Inc. This is a PDF-only article. Log in to Email Alerts with your email address.
Thank you for your interest in spreading the word on Circulation. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Enter multiple addresses on separate lines or separate them with commas. Bookmark this post on del.
Digg this post on digg. Submit this post on reddit. Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question.